Home Cart Sign in  
Chemical Structure| 611168-24-2 Chemical Structure| 611168-24-2

Structure of Glycerol phenylbutyrate
CAS No.: 611168-24-2

Chemical Structure| 611168-24-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Glycerol phenylbutyrate (GPB) acts as a sigma-2 (σ2) receptor ligand with a pKi of 8.02 and functions as a next-generation ammonia scavenger.

Synonyms: HPN-100; GT4P

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Glycerol phenylbutyrate

CAS No. :611168-24-2
Formula : C33H38O6
M.W : 530.65
SMILES Code : O=C(OCC(OC(CCCC1=CC=CC=C1)=O)COC(CCCC2=CC=CC=C2)=O)CCCC3=CC=CC=C3
Synonyms :
HPN-100; GT4P
MDL No. :MFCD28016960
InChI Key :ZSDBFLMJVAGKOU-UHFFFAOYSA-N
Pubchem ID :10482134

Safety of Glycerol phenylbutyrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Glycerol phenylbutyrate

GPCR

Isoform Comparison

Biological Activity

Description
Glycerol phenylbutyrate (GPB) acts as a sigma-2 (σ2) receptor ligand with a pKi of 8.02 and functions as a next-generation ammonia scavenger. GPB is recognized for its potential in treating hyperammonemia and may also hold therapeutic potential for conditions such as chronic hepatic encephalopathy and other inherited metabolic disorders[1].[2].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01949766 Byler Disease NO_LONGER_AVAILABLE - -
NCT01257737 Urea Cycle Disorders PHASE4 COMPLETED 2017-02-16 UCLA Pediatrics/Genetics, Los ... More >>Angeles, California, 90095, United States|Stanford University School of Medicine, Palo Alto, California, 94305, United States|Denver Children's Hospital, Aurora, Colorado, 80045, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|Maine Medical Center, Portland, Maine, 04102, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, 55454, United States|Mount Sinai School of Medicine, New York, New York, 10029, United States|University Hospitals Case Medical Center, Cleveland, Ohio, 44106, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Children's Hospital of Pittsburg of UPMC, Pittsburgh, Pennsylvania, 15224, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|University of Utah, Salt Lake City, Utah, 84112, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, 53226, United States|The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada Less <<
NCT00986895 Hepatic Encephalopathy|Urea Cy... More >>cle Disorders Less << PHASE1 COMPLETED 2025-06-07 National University of Pharmac... More >>y, Kharkiv, 61057, Ukraine|Department of General Surgery #2; Kharkiv State Medical University, Kharkiv, 61128, Ukraine Less <<
NCT01881984 Medium-chain Acyl-CoA Dehydrog... More >>enase (MCAD) Deficiency Less << PHASE1 COMPLETED 2025-02-16 Children's Hospital of Pittsbu... More >>rgh of UPMC, Pittsburgh, Pennsylvania, 15224, United States Less <<
NCT00947297 Urea Cycle Disorders PHASE3 COMPLETED 2025-11-11 Long Beach Memorial, Long Beac... More >>h, California, 90806, United States|UCLA, Los Angeles, California, 90095, United States|Stanford University, Stanford, California, 94305, United States|Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Yale School of Medicine, New Haven, Connecticut, 06510, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|University of Florida, Gainesville, Florida, 32611, United States|Univeristy of Iowa, Iowa City, Iowa, 52242, United States|Maine Medical Center, Portland, Maine, 04102, United States|SNBL-Clinical Pharmacology Center, Baltimore, Maryland, 21201, United States|Tufts-New England Medical Center, Boston, Massachusetts, 02111, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, 55454, United States|Mount Sinai School of Medicine, New York, New York, 10029, United States|Westchester Medical Center, Valhalla, New York, 10595, United States|University Hospitals Case Medical Center, Cleveland, Ohio, 44106, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|University of Utah, Salt Lake City, Utah, 84112, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|The Hospital for Sick Children, Toronto, Ontario, Canada Less <<
NCT01347073 Urea Cycle Disorders PHASE3 COMPLETED 2025-03-13 UCLA Pediatrics/Genetics, Los ... More >>Angeles, California, 90404, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|Maine Medical Center, Portland, Maine, 04101, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|Mount Sinai School of Medicine, New York, New York, 10029, United States|University Hospitals Case Medical Center, Cleveland, Ohio, 44106, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Baylor College of Medicine, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.42mL

1.88mL

0.94mL

18.84mL

3.77mL

1.88mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories